Targeting the atypical chemokine receptor 2 (Ackr2) improves the benefit of anti-PD-1 immunotherapy in melanoma mouse model

Targeting the atypical chemokine receptor 2 (Ackr2) improves the benefit of anti-PD-1 immunotherapy in melanoma mouse model

Immune checkpoint blockade (ICB) therapies, such as anti-PD-1, have transformed cancer treatment, but many patients do not respond due to a non-inflammatory tumor microenvironment (TME). Here, we investigated the impact of targeting Atypical Chemokine Receptor 2 (ACKR2), which scavenges key chemokin...

Full description

Saved in:
Bibliographic Details
Main Authors: Muhammad Zaeem Noman, Martyna Szpakowska, Malina Xiao, Ruize Gao, Kris Van Moer, Akinchan Kumar, Markus Ollert, Guy Berchem, Andy Chevigné, Bassam Janji
Format: Article
Language:English
Published: Taylor & Francis Group 2025-12-01
Series:OncoImmunology
Subjects:
Cancer immunotherapy
ACKR2
immune checkpoint blockade
anti-PD-1
melanoma
combination immunotherapy
Online Access:https://www.tandfonline.com/doi/10.1080/2162402X.2025.2494426
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items